CN1491683A - Chinese medicine adhesive film for preventing and treating coronary heart disease and angina pectoris and its preparing method - Google Patents
Chinese medicine adhesive film for preventing and treating coronary heart disease and angina pectoris and its preparing method Download PDFInfo
- Publication number
- CN1491683A CN1491683A CNA02146524XA CN02146524A CN1491683A CN 1491683 A CN1491683 A CN 1491683A CN A02146524X A CNA02146524X A CN A02146524XA CN 02146524 A CN02146524 A CN 02146524A CN 1491683 A CN1491683 A CN 1491683A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- rhizoma
- thick paste
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 173
- 206010002383 Angina Pectoris Diseases 0.000 title claims abstract description 57
- 208000029078 coronary artery disease Diseases 0.000 title abstract description 29
- 239000002313 adhesive film Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title description 7
- 239000004863 Frankincense Substances 0.000 claims abstract description 17
- 239000000463 material Substances 0.000 claims abstract description 15
- 239000004014 plasticizer Substances 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 96
- 229940079593 drug Drugs 0.000 claims description 69
- 239000000843 powder Substances 0.000 claims description 54
- 241000628997 Flos Species 0.000 claims description 44
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 44
- 235000015511 Liquidambar orientalis Nutrition 0.000 claims description 36
- 241000736148 Styrax Species 0.000 claims description 36
- 239000004870 Styrax Substances 0.000 claims description 36
- 235000000126 Styrax benzoin Nutrition 0.000 claims description 36
- 238000011282 treatment Methods 0.000 claims description 35
- 239000000706 filtrate Substances 0.000 claims description 33
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 28
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 25
- 241000180649 Panax notoginseng Species 0.000 claims description 25
- 230000006837 decompression Effects 0.000 claims description 22
- 239000007788 liquid Substances 0.000 claims description 22
- 238000003756 stirring Methods 0.000 claims description 22
- 241000717739 Boswellia sacra Species 0.000 claims description 21
- 241000218176 Corydalis Species 0.000 claims description 21
- 241001057584 Myrrha Species 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 239000004480 active ingredient Substances 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 19
- 239000000284 extract Substances 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 18
- 210000000582 semen Anatomy 0.000 claims description 18
- 238000002156 mixing Methods 0.000 claims description 15
- 239000000796 flavoring agent Substances 0.000 claims description 13
- 235000019634 flavors Nutrition 0.000 claims description 13
- 238000005325 percolation Methods 0.000 claims description 13
- 239000009636 Huang Qi Substances 0.000 claims description 12
- 239000002671 adjuvant Substances 0.000 claims description 12
- 239000004744 fabric Substances 0.000 claims description 12
- 239000011159 matrix material Substances 0.000 claims description 12
- 238000001556 precipitation Methods 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 11
- 238000010411 cooking Methods 0.000 claims description 10
- 238000000895 extractive distillation Methods 0.000 claims description 10
- 238000000465 moulding Methods 0.000 claims description 10
- 229940126680 traditional chinese medicines Drugs 0.000 claims description 10
- 239000000341 volatile oil Substances 0.000 claims description 10
- 241000545442 Radix Species 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 9
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims description 6
- 238000007598 dipping method Methods 0.000 claims description 6
- 235000010603 pastilles Nutrition 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 241000407170 Curcuma Species 0.000 claims description 5
- 235000014375 Curcuma Nutrition 0.000 claims description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 5
- 238000011084 recovery Methods 0.000 claims description 5
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims description 4
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 4
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 4
- 241000219780 Pueraria Species 0.000 claims description 3
- 230000017531 blood circulation Effects 0.000 abstract description 9
- 230000004217 heart function Effects 0.000 abstract description 8
- 210000002216 heart Anatomy 0.000 abstract description 7
- 210000004204 blood vessel Anatomy 0.000 abstract description 6
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 235000003717 Boswellia sacra Nutrition 0.000 abstract 1
- 235000012035 Boswellia serrata Nutrition 0.000 abstract 1
- 240000007551 Boswellia serrata Species 0.000 abstract 1
- 241000234653 Cyperus Species 0.000 abstract 1
- 235000002848 Cyperus flabelliformis Nutrition 0.000 abstract 1
- 235000010575 Pueraria lobata Nutrition 0.000 abstract 1
- 244000046146 Pueraria lobata Species 0.000 abstract 1
- 240000000513 Santalum album Species 0.000 abstract 1
- 235000008632 Santalum album Nutrition 0.000 abstract 1
- 239000002674 ointment Substances 0.000 abstract 1
- 244000138993 panchioli Species 0.000 abstract 1
- 239000002023 wood Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 41
- 210000003516 pericardium Anatomy 0.000 description 41
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- 239000002904 solvent Substances 0.000 description 15
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 13
- 229940093252 sorbitrate Drugs 0.000 description 13
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 11
- 208000002193 Pain Diseases 0.000 description 10
- 125000003118 aryl group Chemical group 0.000 description 10
- 235000011187 glycerol Nutrition 0.000 description 9
- 208000031225 myocardial ischemia Diseases 0.000 description 9
- 230000036407 pain Effects 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 230000002107 myocardial effect Effects 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 102000004420 Creatine Kinase Human genes 0.000 description 7
- 108010042126 Creatine kinase Proteins 0.000 description 7
- 230000000302 ischemic effect Effects 0.000 description 7
- 230000001276 controlling effect Effects 0.000 description 6
- 229940072981 nitro-dur Drugs 0.000 description 6
- 230000036284 oxygen consumption Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 230000004087 circulation Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000003292 glue Substances 0.000 description 5
- 229940074869 marquis Drugs 0.000 description 5
- VBUNOIXRZNJNAD-UHFFFAOYSA-N ponazuril Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 VBUNOIXRZNJNAD-UHFFFAOYSA-N 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000008828 contractile function Effects 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 230000002085 persistent effect Effects 0.000 description 4
- 230000000284 resting effect Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000002861 ventricular Effects 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000002045 lasting effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000005086 pumping Methods 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- -1 sorbitol phthalic acid ester Chemical class 0.000 description 3
- 210000000115 thoracic cavity Anatomy 0.000 description 3
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 230000003288 anthiarrhythmic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- ZBELDPMWYXDLNY-UHFFFAOYSA-N methyl 9-(4-bromo-2-fluoroanilino)-[1,3]thiazolo[5,4-f]quinazoline-2-carboximidate Chemical compound C12=C3SC(C(=N)OC)=NC3=CC=C2N=CN=C1NC1=CC=C(Br)C=C1F ZBELDPMWYXDLNY-UHFFFAOYSA-N 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000010117 myocardial relaxation Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-N o-dicarboxybenzene Natural products OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229940126532 prescription medicine Drugs 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007560 sedimentation technique Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- XNRNNGPBEPRNAR-JQBLCGNGSA-N thromboxane B2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1OC(O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O XNRNNGPBEPRNAR-JQBLCGNGSA-N 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The Chinese medicine adhesive film for preventing and treating coronary heart disease and angina pectoris consists of back lining material, medicine layer and protecting film. The medicine layer consists of skeleton supplementary material, effective Chinese medicine extractive and plasticizer; and the effective Chinese medicine extractive is ointment of extractive of Chuanxiong rhizome, sandalwood, nutagrass flatsedge rhizome, dalbergia wood, frankincense, kudzu vine root, etc. The Chinese medicine adhesive film is adhered to left chest for transdermal absorption to act on heart, and can dilate coronary blood vessel, improve blood flow of coronary blood vessel, improve heart function and prevent hidden coronary heart disease.
Description
Technical field
The present invention relates to a kind of Chinese medicine pad pasting of angina pectoris and its preparation process of this pad pasting prevented and treated.
Technical background
Coronary heart disease is the human particularly commonly encountered diseases and the frequently-occurring disease of middle-aged and elderly people, is first disease that causes global human death.Along with human society aging, expanding economy and growth in the living standard, sickness rate increases day by day and becomes younger gradually.The many genus middle and advanced stage patient who seeks medical advice to hospital in the society has tangible symptom and heart ischemia to sexually revise, and needs active treatment.In addition some crowd suffers from latent coronary heart disease, non-evident sympton, but in case be subjected to the stimulation of extraneous different factors, bring out the outbreak of angina pectoris at any time.Some people is because psychentonia, operating pressure are big, and higher fatty acid in the diet, high protein, high-carbohydrate material increase, and add the shortage physical exertion, are in sub-health state, very likely develop to coronary heart disease.At cardiovascular and cerebrovascular disease patient crowd's lasting expansion with become younger, the expert advocates the measure of " putting prevention first and combining prevention with control " energetically.International classical medicine aspirin has the anti-platelet aggregation effect, is applied to the prevention of coronary heart disease gradually, but this medicine has a lot of effects of paying, and takes in a large number for a long time easily to cause poisoning even threat to life.At present, numerous to the medication of middle and advanced stage coronary heart disease patient both at home and abroad, but lack effective, safe prophylactic.To latent coronary heart disease and sub-health population, do not pay attention to as yet, more there is not preventive measure.
The eighties in 20th century, to develop Western medicine nitro-dur percutaneous abroad and absorb treatment coronary heart disease, the characteristics of this type of dosage form are: do not take medicine, do not have an injection, percutaneous dosing, patient does not have for a long time the misery of taking medicine, having an injection; Peak-paddy the phenomenon of no oral or injecting drug use blood drug level, percutaneous dosing blood drug level steadily, lasting; Medicine is without the destruction and the Degradation of stomach, liver enzyme.Although the nitro-dur good effect, its pair effect is bigger, and serious drug resistance is arranged.The traditional Chinese medical science is thought: coronary heart disease system " thoracic obstruction ", " chest pain ", " angina pectoris ".Because the heart, liver, kidney, YANG QI deficiency, blood fortune is sluggish, and the blood resistance causes blockage of the cardiac vessels, and QI and blood is obstructed, stagnation of QI and blood may bring about pain.The Chinese medicine preparation of at present existing many treatment angina pectoris, a kind of manufacture method of preventing and treating the coronary heart disease medicine for external use is for example disclosed among the CN1030183A, it be with have blood circulation promoting and blood stasis dispelling, eliminating phlegm dampness removing, diffusion blood vessel, causing resuscitation with aromatic drugs, twenty flavor Chinese medicine dryings such as the Radix Scrophulariae of enriching blood, going into various effects such as the god of Dingan County of regulating the flow of vital energy, Radix Angelicae Sinensis, Rhizoma Acori Graminei, Pericarpium Zanthoxyli, Ramulus Cinnamomi, Bulbus Allii Macrostemonis, Borneolum Syntheticum, Radix Notoginseng, pulverize, sieve, mixing and stirring, make medicated bag, put left front, be used to prevent and treat coronary heart disease.Life-time service does not have the effect of paying.Though but this medicated bag has certain curative effect, because it is not that medicine is directly contacted with human body skin, limited to the Transdermal absorption of medicine, really by just some volatile ingredients of skin absorbs, so had a strong impact on clinical efficacy.Select other externally used pastes of Chinese medicine for use, there is the following problem that can't overcome, a little less than herbal nature, the effective components of Chinese medicinal extract is dispersed in the macromolecule glue, not only drug loading is few, and the rate of release of effective ingredient is slow, causes blood drug level low, therefore can only treat the body surface disease, not reach the requirement that prevents and treats coronary heart disease; Common drying and moulding more than 60 ℃ in the preparation of Chinese medicine externally used paste has destroyed effective components of Chinese medicinal, influences the curative effect of Chinese medicine exterior-applied formulation.The exterior-applied formulation that macromolecule glue,medicinal and medicament mixed are made, easy close adhesion makes skin airtight on the external application skin, influences the drainage of the homergy and the secretions of local skin, patient does not feel well yet, and should not paste for a long time.It is very difficult that above-mentioned these technical problems make that present Chinese medicine exterior-applied formulation prepares the medicine of effectively preventing coronary heart disease.Therefore, need at present a kind ofly can overcome the exterior-applied formulation that above-mentioned defective is effectively treated coronary heart disease.
Summary of the invention
Purpose of the present invention has just provided a kind of Chinese medicine pad pasting of effective control angina pectoris.
Another purpose of the present invention has provided the preparation method of this Chinese medicine pad pasting.
The present invention prevents and treats the Chinese medicine pad pasting of angina pectoris and is made up of back lining materials, medicated layer and protecting film, medicated layer wherein is made up of matrix type adjuvant 23 ~ 25%, middle pharmaceutically active ingredient 68 ~ 70% and plasticizer 7%, wherein said plasticizer is one or more in glycerol, triacetyl glycerine, ethylene glycol, the sorbitol phthalic acid ester, preferably glycerine; Wherein said matrix type adjuvant is natural polysaccharide and in synthetic polymer such as polyvinyl alcohol, Pioloform, polyvinyl acetal, polyvinylpyrrolidone, polyacrylate or the polyacrylamide one or more, preferably polyethylene alcohol.
The middle pharmaceutically active ingredient that the present invention selects for use is that kinds of traditional Chinese medicines is made up, and these Chinese crude drugs can directly be ground into Chinese medicine powder, also can the partly process extraction of part levigation.
The Chinese medicine that the present invention selects for use mainly is drugs of causing resuscitation by administering aromatic drugs, and they have the synergism of eliminating turbid pathogen with aromatics, activating QI to alleviate the depression, understand things pain-stopping, thereby realizes the present invention.Wherein said drugs of causing resuscitation by administering aromatic drugs is Styrax, Borneolum Syntheticum, Benzoinum and Rhizoma Acori Graminei; The preferred consumption of these Chinese medicine composition is Styrax 3-7 part, Borneolum Syntheticum 1-3 part, Benzoinum 1-3 part and Rhizoma Acori Graminei 1-3 part, 1.93 parts of 5.2 parts of preferred Styrax, 1.93 parts of Borneolum Syntheticums, 1.93 parts of Benzoinumes and Rhizoma Acori Graminei.
In another preferred embodiment of the present invention, except above-mentioned drugs of causing resuscitation by administering aromatic drugs, also comprise drug for invigorating blood circulation and eliminating stasis, the same usefulness of drugs of causing resuscitation by administering aromatic drugs and drug for invigorating blood circulation and eliminating stasis assists drugs of causing resuscitation by administering aromatic drugs to open blood stasis, promoting blood circulation, pain relieves the pain.Described drug for invigorating blood circulation and eliminating stasis is selected from: one or more in Rhizoma Chuanxiong, Radix Salviae Miltiorrhizae, Radix Notoginseng, Radix Angelicae Sinensis, Radix Paeoniae Rubra, Olibanum, Myrrha, Rhizoma Corydalis and the Radix Curcumae; If select, the consumption of these blood circulation promoting and blood stasis dispelling is respectively: Rhizoma Chuanxiong 3-7 part, Radix Salviae Miltiorrhizae 3-7 part, Radix Notoginseng 3-7 part, Radix Angelicae Sinensis 1-3 part, Radix Paeoniae Rubra 1-3 part, Olibanum 1-3 part, Myrrha 1-3 part, Rhizoma Corydalis 1-3 part, Radix Curcumae 1-3 part, 1.93 parts of 5.2 parts of preferred Rhizoma Chuanxiongs, 5.2 parts of Radix Salviae Miltiorrhizaes, 5.2 parts of Radix Notoginseng, 1.93 parts of Radix Angelicae Sinensis, 1.93 parts of Radix Paeoniae Rubra, 1.93 parts of Olibanums, 1.93 parts of Myrrhas, 1.93 parts of Rhizoma Corydalis and Radix Curcumaes.
In yet another embodiment of the present invention, except that above-mentioned two class medicines, also comprise the promoting the circulation of QI to relieve pain medicine.The promoting the circulation of QI to relieve pain medicine assists drugs of causing resuscitation by administering aromatic drugs to open the stagnation of QI, and the capable then blood of gas is capable, and the capable then expectorant of gas disappears, thereby alleviates the pain that the stagnation of QI, blood stasis, the stagnation of phlegm thoracic obstruction cause.Described promoting the circulation of QI to relieve pain medicine is selected from: one or more in Rhizoma Cyperi, the Radix Aucklandiae, Lignum Dalbergiae Odoriferae, Lignum Santali Albi, Lignum Aquilariae Resinatum, the Radix Angelicae Dahuricae, Flos Caryophylli, the Bulbus Allii Macrostemonis.If select for use, the consumption of these promoting the circulation of QI to relieve pain medicines is respectively: Rhizoma Cyperi 1-3 part, Radix Aucklandiae 1-3 part, Lignum Dalbergiae Odoriferae 1-3 part, Lignum Santali Albi 1-3 part, Lignum Aquilariae Resinatum 1-3 part, Radix Angelicae Dahuricae 1-3 part, Flos Caryophylli 1-3 part, Bulbus Allii Macrostemonis 1-3 part, 1.93 parts of 1.93 parts of preferred Rhizoma Cyperis, 1.93 parts of the Radix Aucklandiae, 1.93 parts of Lignum Dalbergiae Odoriferaes, 1.93 parts in Lignum Santali Albi, 1 part of Lignum Aquilariae Resinatum, 1.93 parts of the Radixs Angelicae Dahuricae, 1 part of Flos Caryophylli and Bulbus Allii Macrostemonis.
In addition, in the preferred embodiment of the present invention, also comprise the purging liver-fire medicine, it not only can assist drugs of causing resuscitation by administering aromatic drugs that the irritability accent is reached, and dredges and rushes down appropriateness, can suppress the unlikely too hot warm-dryness syndrome of all incense drugs again and split.Described purging liver-fire medicine is selected from one or more in Semen Cassiae, the Flos Chrysanthemi.If select for use, the consumption of these purging liver-fire medicines is respectively: Flos Chrysanthemi 1-4 part and Semen Cassiae 1-3 part, 1.93 parts of 2.87 parts of preferred Flos Chrysanthemis and Semen Cassiaes.
In the most preferred embodiment of the present invention, also comprise Qi-tonifying drug, it both can assist drugs of causing resuscitation by administering aromatic drugs QI invigorating row to stagnate, and the mediation blood vessels again can tonifying QI to produce body fluid, to remedy the fraud of hot incense drug consumption impairment of QI liquid.Described Qi-tonifying drug is selected from one or both in the Radix Astragali, Caulis Polygoni Multiflori and the Radix Puerariae.If select for use, the consumption of these Qi-tonifying drugs is respectively: Radix Astragali 1-3 part, Caulis Polygoni Multiflori 1-3 part and Radix Puerariae 1-4 part, 2.87 parts of 1.93 parts of the preferred Radixs Astragali, 1.93 parts of Caulis Polygoni Multiflori and Radix Puerariaes.
The present invention preferably extracts the active component of preparation pad pasting of the present invention with the Chinese crude drug of following consumption:
Styrax 3-7 part, Borneolum Syntheticum 1-3 part, Benzoinum 1-3 part, Rhizoma Acori Graminei 1-3 part
Rhizoma Cyperi 1-3 part, Radix Aucklandiae 1-3 part, Lignum Dalbergiae Odoriferae 1-3 part, Lignum Santali Albi 1-3 part, Lignum Aquilariae Resinatum 1-3 part, Radix Angelicae Dahuricae 1-3 part
Flos Caryophylli 1-3 part, Bulbus Allii Macrostemonis 1-3 part, Rhizoma Chuanxiong 3-7 part, Radix Salviae Miltiorrhizae 3-7 part, Radix Notoginseng 3-7 part, Radix Angelicae Sinensis 1-3 part
Radix Paeoniae Rubra 1-3 part, Olibanum 1-3 part, Myrrha 1-3 part, Rhizoma Corydalis 1-3 part, Radix Curcumae 1-3 part
Flos Chrysanthemi 1-4 part, Radix Astragali 1-3 part, Caulis Polygoni Multiflori 1-3 part, Semen Cassiae 1-3 part, Radix Puerariae 1-4 part.
The present invention especially preferably extracts the pad pasting active component made from the Chinese crude drug of following consumption:
5.2 parts of Styrax, 1.93 parts of Borneolum Syntheticums, 1.93 parts of Benzoinumes, 1.93 parts of 1.93 portions of Rhizoma Cyperis of Rhizoma Acori Graminei, 1.93 parts of the Radix Aucklandiae, 1.93 parts of Lignum Dalbergiae Odoriferaes, 1.93 parts in Lignum Santali Albi, 1 part of Lignum Aquilariae Resinatum, 1.93 parts of the Radixs Angelicae Dahuricae, 1 part of Flos Caryophylli, 5.2 parts of Rhizoma Chuanxiongs, 5.2 parts of Radix Salviae Miltiorrhizaes, 5.2 parts of Radix Notoginseng, 1.93 parts of Radix Angelicae Sinensis, 1.93 parts of Radix Paeoniae Rubra, 1.93 parts of Olibanums, 1.93 parts of Myrrhas, 1.93 parts of Rhizoma Corydalis, 1.93 parts of Radix Curcumaes, 1.93 parts of Bulbus Allii Macrostemonis
2.87 parts of Flos Chrysanthemis, 1.93 parts of the Radixs Astragali, 1.93 parts of Caulis Polygoni Multiflori, 1.93 parts of Semen Cassiaes, 2.87 parts of Radix Puerariaes.
Prescription compatibility of the present invention has been broken through the thinking of Chinese medicine conventional formulation, discuss angina pectoris pathogeny, pathoanatomical variation and Therapeutic Principle according to the Chinese and western medical scientific principle, utilize medicine cooperatively interact performance synergism, improve aspect such as Chinese medicine curative effect and carry out prescription, determined curative effect, safety do not have the effect of paying.During its performance of principal agent in the side (monarch, ministerial drug) all meets, the theoretical requirement of western medical treatment coronary heart disease, synthetic prescription improves the Chinese medicine curative effect greatly comprehensively.The invention belongs to pure compound Chinese medicinal preparation, prescription medicine form both had causing resuscitation with aromatic drugs, blood circulation promoting and blood stasis dispelling, numbness relieving and pain relieving, the effect that fills blood, have dilating coronary blood vessel, coronary blood flow increasing again, improve the myocardial ischemia-anoxemia equilibrium of supply and demand, reduce myocardial oxygen consumption, strengthen the effect of cardiac function, blood viscosity lowering.
Extracting method can adopt various extracting method pharmaceutically commonly used such as percolation, decoction and alcohol sedimentation technique, ethanol extract from water precipitation etc.Preferably adopt different extracting method to be extracted respectively to various different classes of medicines.For example Rhizoma Chuanxiong, Lignum Santali Albi, Radix Curcumae, Flos Caryophylli, Radix Angelicae Sinensis, Rhizoma Acori Graminei, Rhizoma Cyperi, Lignum Dalbergiae Odoriferae, Bulbus Allii Macrostemonis, Lignum Aquilariae Resinatum, Flos Chrysanthemi, the Radix Angelicae Dahuricae, Olibanum, the active ingredient of Myrrha Chinese crude drug water extraction, filtrate is condensed into thick paste, adding amount of alcohol is that 60% composition is stirred to fully evenly, left standstill 24 hours, draw supernatant, the precipitation part filters filtrate decompression, reclaim ethanol, it is standby that reheat is condensed into thick paste; The alcohol extraction active ingredient: Radix Salviae Miltiorrhizae, the Radix Astragali, Radix Paeoniae Rubra, Radix Puerariae, Benzoinum, Rhizoma Corydalis Chinese medicine are added 9 times of amount ethanol extractions 2 times, each 1 hour, filter the back twice filtrate is merged decompression, reclaim ethanol, it is standby that medicinal liquid is condensed into thick paste; Percolation extracts the medicine active ingredient: during the alcohol dipping 24 of Caulis Polygoni Multiflori, the medicinal 12 times of amounts of Semen Cassiae 2 flavors, carry out percolation, collect percolate, reclaim ethanol, it is standby to be condensed into thick paste; Borneolum Syntheticum with Radix Notoginseng powder is broken into attritive powder and Styrax is standby; Thick paste and Borneolum Syntheticum, Radix Notoginseng powder and Styrax mixing and stirring with above steps is extracted do not produce to there being minute bubbles, leave standstill 10～30 minutes, promptly get compound.
The preparation that prevents and treats the pastille pad pasting of coronary heart disease pad pasting of the present invention is that Chinese medicine mixing active ingredients cream, polyvinyl alcohol and glycerol three are fully mixed stirring, do not produce or the minute bubbles complete obiteration to there being minute bubbles, left standstill 20～30 minutes, mix thick paste and evenly be coated with fabric film with film-making machine, under the room temperature behind the dry forming, cut into strip, make medicated layer, preferred effective components of Chinese medicinal compound 68%, polyvinyl alcohol 25% and glycerol 7%.
The preparation that prevents and treats the coronary heart disease pad pasting of the present invention is that medicated layer is fixed on the back lining materials, and fixing means is that the both sides with medicated layer are sticking with glue, and is perhaps sticking with glue four jiaos of medicated layer and every limit mid point fixing.Back lining materials is sarashi kanakin or non-woven fabrics.
The pad pasting another side of preventing and treating coronary heart disease of the present invention can have protecting film, and protecting film is plastic sheeting, cellophane etc.
The pad pasting of preventing and treating coronary heart disease of the present invention spreads on the left breast pareordia skin, medicine dissociates out from mesh fast, and transdermal absorbs through subcutaneous blood capillary and enters the body circulation, without the destruction and the degraded of gastrointestinal and liver enzyme, blood drug level is high and lasting, reaches the effect of preventing and treating coronary heart disease.Pad pasting using method of preventing and treating coronary heart disease of the present invention was 2 of consumptions first, changed a slice every 2 ~ 4 days, shared 6 of course of treatment.
The pad pasting of preventing and treating coronary heart disease of the present invention is the pbz polymer glue,medicinal not, does not closely stick together with skin on the external application skin, does not influence the eliminating of the homergy and the secretions of local skin, and patient feels comfortably cool, but life-time service to skin without any sense of discomfort.
The Chinese medicine pad pasting of control angina pectoris of the present invention can effectively prevent angina pectoris, in also can effectively preventing and treat, late period coronary heart disease, can be used for the prevention of latent coronary heart disease etc. again, prevent the outbreak of coronary heart disease or delay outbreak cycle of coronary heart disease, to people's group energy prevention of sub-health state or postpone that coronary heart disease takes place or development.
The Chinese medicine pad pasting animal drugs of control angina pectoris of the present invention is imitated and learned the experiment demonstration: this Chinese medicine pad pasting has anti-myocardial infarction effect, and strengthens infarct size with dosage and dwindle; Lactic acid dehydrogenase (LDH) in the serum when resisting myocardial ischemia, the effect that creatine phosphokinase (CPK) and malonaldehyde (MDA) raise; There is the ischemic of improvement ECG ST section to change and antiarrhythmic effect; The contractile function of ischemic myocardial and the infringement of diastolic function there is certain protective role.
The preparation of embodiment 1 control angina pectoris external Chinese medicine pad pasting
A) take by weighing Chinese crude drug by following consumption:
Styrax 234g, Borneolum Syntheticum 87g, Benzoinum 87g and Rhizoma Acori Graminei 87g;
Rhizoma Acori Graminei with adding decocting in water 10 ~ 12 hours, the volatile oil that extractive distillation goes out, water cooking liquid filters, filtrate is condensed into thick paste, adding amount of alcohol is 60%, is stirred well to fully evenly, leaves standstill 24 hours, draws supernatant, the precipitation part filters, and filtrate decompression reclaims ethanol, and reconcentration becomes thick paste standby;
B) the ethanol of Benzoinum with 9 times of amounts, reflux, extract, 2 times, each 1 hour, filter, 2 filtrates are merged decompression, reclaim ethanol, it is standby that medicinal liquid is condensed into thick paste;
C) it is standby Borneolum Syntheticum powder to be broken into superfine powder, and Styrax is standby;
D) thick paste that makes in the step b), the whole mixing of fine powder in the step c) are stirred, produce or the bubble complete obiteration, left standstill 10 ~ 15 minutes to there being minute bubbles;
E) the mixing thick paste in the step d), matrix type adjuvant and glycerol three are fully mixed, stir, do not produce or the bubble complete obiteration, left standstill 20 ~ 30 minutes, put system film in the film-making machine medicine groove to there being minute bubbles;
F) the medicine film in the step g) is dry at normal temperatures or below 40 ℃, cut into lamellar after the molding, place on the adhesive-bonded fabric dressing and fix according to the both sides fixed form;
G) paste covering at the medicated layer opposite side.
The preparation of embodiment 2 control angina pectoris external Chinese medicine pad pastings
A) take by weighing Chinese crude drug by following consumption: Styrax 234g, Borneolum Syntheticum 87g, Benzoinum 87g, Rhizoma Acori Graminei 87g, Rhizoma Cyperi 87g, Radix Aucklandiae 87g, Lignum Dalbergiae Odoriferae 87g, Lignum Santali Albi 87g, Lignum Aquilariae Resinatum 45g, Radix Angelicae Dahuricae 87g, Flos Caryophylli 45g and Bulbus Allii Macrostemonis 87g;
B) Rhizoma Cyperi, the Radix Aucklandiae, Lignum Dalbergiae Odoriferae, Lignum Santali Albi, Lignum Aquilariae Resinatum, the Radix Angelicae Dahuricae, Flos Caryophylli, Bulbus Allii Macrostemonis, Rhizoma Acori Graminei Chinese crude drug with adding decocting in water 10 ~ 12 hours, the volatile oil that extractive distillation goes out, water cooking liquid filters, and filtrate is condensed into thick paste, adding amount of alcohol is 60%, be stirred well to fully evenly, left standstill 24 hours, draw supernatant, the precipitation part filters, filtrate decompression reclaims ethanol, and reconcentration becomes thick paste standby;
C) the ethanol of 9 times of amounts of Benzoinum Chinese medicine adding, reflux, extract, 2 times, each 1 hour, filter, 2 filtrates are merged decompression, reclaim ethanol, it is standby that medicinal liquid is condensed into thick paste;
D) Borneolum Syntheticum powder is broken into superfine powder, Styrax is standby;
E) with step b), c) in the thick paste, the fine powder in the step d) that make all mix and stir, produce or the bubble complete obiteration to there being minute bubbles, left standstill 10 ~ 15 minutes;
F) the mixing thick paste in the step e), matrix type adjuvant and glycerol three are fully mixed, stir, do not produce or the bubble complete obiteration, left standstill 20 ~ 30 minutes, put system film in the film-making machine medicine groove to there being minute bubbles;
G) the medicine film in the step f) is dry at normal temperatures or below 40 ℃, cut into lamellar after the molding, place on the adhesive-bonded fabric dressing and fix according to the both sides fixed form;
H) paste protecting film at the medicated layer opposite side.
The preparation of embodiment 3 control angina pectoris external Chinese medicine pad pastings
A) take by weighing Chinese crude drug by following consumption:
Styrax 234g, Borneolum Syntheticum 87g, Benzoinum 87g, Rhizoma Acori Graminei 87g, Rhizoma Cyperi 87g, Radix Aucklandiae 87g, Lignum Dalbergiae Odoriferae 87g, Lignum Santali Albi 87g, Lignum Aquilariae Resinatum 45g, Radix Angelicae Dahuricae 87g, Flos Caryophylli 45g, Rhizoma Chuanxiong 234g, Radix Salviae Miltiorrhizae 234g, Radix Notoginseng 234g, Radix Angelicae Sinensis 87g, Radix Paeoniae Rubra 87g, Olibanum 87g, Myrrha 87g, Rhizoma Corydalis 87g, Radix Curcumae 87g and Bulbus Allii Macrostemonis 87g;
B) Rhizoma Chuanxiong, Lignum Santali Albi, Radix Curcumae, the Radix Aucklandiae, Flos Caryophylli, Radix Angelicae Sinensis, Rhizoma Acori Graminei, Rhizoma Cyperi, Lignum Dalbergiae Odoriferae, Bulbus Allii Macrostemonis, Lignum Aquilariae Resinatum, the Radix Angelicae Dahuricae, Olibanum, Myrrha Chinese crude drug with adding decocting in water 10 ~ 12 hours, the volatile oil that extractive distillation goes out, water cooking liquid filters, and filtrate is condensed into thick paste, adding amount of alcohol is 60%, be stirred well to fully evenly, left standstill 24 hours, draw supernatant, the precipitation part filters, filtrate decompression reclaims ethanol, and reconcentration becomes thick paste standby;
C) the ethanol of Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Radix Notoginseng, Benzoinum, 9 times of amounts of Rhizoma Corydalis Chinese medicine adding, reflux, extract, 2 times, each 1 hour, filter, 2 filtrates are merged decompression, reclaim ethanol, it is standby that medicinal liquid is condensed into thick paste;
D) it is standby Borneolum Syntheticum, Radix Notoginseng 2 flavor medicated powder to be broken into superfine powder, and Styrax is standby;
E) with step b) and c) in the thick paste, the fine powder in the step d) that make all mix and stir, produce or the bubble complete obiteration to there being minute bubbles, left standstill 10 ~ 15 minutes;
F) the mixing thick paste in the step e), matrix type adjuvant and glycerol three are fully mixed, stir, do not produce or the bubble complete obiteration, left standstill 20 ~ 30 minutes, put system film in the film-making machine medicine groove to there being minute bubbles;
G) the medicine film in the step f) is dry at normal temperatures or below 40 ℃, cut into lamellar after the molding, place on the adhesive-bonded fabric dressing and fix according to the both sides fixed form;
H) paste protecting film at the medicated layer opposite side.
The preparation of embodiment 4 control angina pectoris external Chinese medicine pad pastings
A) take by weighing each medicinal raw material in the prescription according to following consumption:
Rhizoma Chuanxiong 234g Lignum Santali Albi 87g Radix Curcumae 87g Lignum Aquilariae Resinatum 45g Rhizoma Cyperi 87g Lignum Dalbergiae Odoriferae 87g Olibanum 87g Myrrha 87g
Flos Chrysanthemi 129g Flos Caryophylli 45g Radix Angelicae Sinensis 87g Radix Angelicae Dahuricae 87g Bulbus Allii Macrostemonis 87g Rhizoma Acori Graminei 87g Radix Salviae Miltiorrhizae 234g rests in peace
Fragrant 87g Radix Paeoniae Rubra 87g Rhizoma Corydalis 87g Semen Cassiae 87g Styrax 234g Borneolum Syntheticum 87g Radix Notoginseng 234g and Radix Aucklandiae 87g;
B) Rhizoma Chuanxiong, Lignum Santali Albi, Radix Curcumae, Flos Caryophylli, Radix Angelicae Sinensis, the Radix Aucklandiae, Rhizoma Acori Graminei, Rhizoma Cyperi, Lignum Dalbergiae Odoriferae, Bulbus Allii Macrostemonis, Lignum Aquilariae Resinatum, Flos Chrysanthemi, the Radix Angelicae Dahuricae, Olibanum, Myrrha Chinese crude drug with adding decocting in water 10 ~ 12 hours, the volatile oil that extractive distillation goes out, water cooking liquid filters, and filtrate is condensed into thick paste, adding amount of alcohol is 60%, be stirred well to fully evenly, left standstill 24 hours, draw supernatant, the precipitation part filters, filtrate decompression reclaims ethanol, and reconcentration becomes thick paste standby;
C) the ethanol of Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Radix Notoginseng, Benzoinum, 9 times of amounts of Rhizoma Corydalis Chinese medicine adding, reflux, extract, 2 times, each 1 hour, filter, 2 filtrates are merged decompression, reclaim ethanol, it is standby that medicinal liquid is condensed into thick paste;
D) Semen Cassiae flavor medicated powder is broken into coarse powder,,, carries out percolation with the alcohol dipping of 12 times of amounts 24 hours according to fluid extract and extractum item percolation down, the collection percolate, recovery ethanol, it is standby to be condensed into thick paste;
E) it is standby Borneolum Syntheticum, Radix Notoginseng 2 flavor medicated powder to be broken into superfine powder, and Styrax is standby;
F) with step b), c), d) in the thick paste, the fine powder in the step e) and the Styrax that make all mix and stir, produce or the bubble complete obiteration to there being minute bubbles, left standstill 10 ~ 15 minutes;
G) the mixing thick paste in the step f), matrix type adjuvant and glycerol three are fully mixed, stir, do not produce or the bubble complete obiteration, left standstill 20 ~ 30 minutes, put system film in the film-making machine medicine groove to there being minute bubbles;
H) the medicine film in the step g) is dry at normal temperatures or below 40 ℃, cut into lamellar after the molding, place on the adhesive-bonded fabric dressing and fix according to the both sides fixed form;
1) pastes protecting film at the medicated layer opposite side.
The preparation of guarantor's pericardium Chinese medicine pad pasting of embodiment 5 control angina pectoris
A) take by weighing each medicinal raw material in the prescription according to following consumption:
Rhizoma Chuanxiong 234g Lignum Santali Albi 87g Radix Curcumae 87g Lignum Aquilariae Resinatum 45g Rhizoma Cyperi 87g
Lignum Dalbergiae Odoriferae 87g Olibanum 87g Myrrha 87g Flos Chrysanthemi 129g Flos Caryophylli 45g
Radix Angelicae Sinensis 87g Radix Angelicae Dahuricae 87g Bulbus Allii Macrostemonis 87g Rhizoma Acori Graminei 87g Radix Salviae Miltiorrhizae 234g
Benzoinum 87g Radix Astragali 87g Radix Paeoniae Rubra 87g Rhizoma Corydalis 87g Caulis Polygoni Multiflori 87g
Semen Cassiae 87g Styrax 234g Borneolum Syntheticum 87g Radix Notoginseng 234g Radix Puerariae 129g;
B) Rhizoma Chuanxiong, Lignum Santali Albi, Radix Curcumae, Flos Caryophylli, Radix Angelicae Sinensis, Rhizoma Acori Graminei, Rhizoma Cyperi, Lignum Dalbergiae Odoriferae, Bulbus Allii Macrostemonis, Lignum Aquilariae Resinatum, Flos Chrysanthemi, the Radix Angelicae Dahuricae, Olibanum, Myrrha Chinese crude drug are used heating decocting in water 10～12 hours, the volatile oil that extractive distillation goes out (water cooking liquid filtration) filtrate is condensed into thick paste, adding amount of alcohol is that 60% composition is stirred to fully evenly, left standstill 24 hours, draw supernatant, the precipitation part filters filtrate decompression, reclaim ethanol, it is standby that reheat is condensed into thick paste;
C) Radix Salviae Miltiorrhizae, the Radix Astragali, Radix Paeoniae Rubra, Radix Puerariae, Benzoinum, Rhizoma Corydalis Chinese medicine are added 9 times of amount ethanol extractions 2 times, each 1 hour, filter the back twice filtrate is merged decompression, reclaim ethanol, it is standby that medicinal liquid is condensed into thick paste;
D) Caulis Polygoni Multiflori and Semen Cassiae 2 flavor medicines according to fluid extracts and extractum item percolation down, during with the alcohol dipping 24 of 12 times of amounts, carry out percolation, the collection percolate, recovery ethanol, it is standby to be condensed into thick paste;
E) it is standby Borneolum Syntheticum and Styrax to be ground into attritive powder;
F) with step b), c) and d) above-mentioned thick paste and Borneolum Syntheticum, Radix Notoginseng powder, the abundant mixing and stirring of Styrax, produce to there being minute bubbles, left standstill 10～30 minutes, promptly get compound;
G) compound 68%, polyvinyl alcohol 25% and the glycerol 7% that obtains in district's above-mentioned steps, the three fully mixes stirring, does not produce or the minute bubbles complete obiteration to there being minute bubbles, leaves standstill 20～30 minutes;
H) get the mixing thick paste that above-mentioned steps makes and evenly be coated with fabric film, behind the dry forming, cut into strip 6cm * 5cm * 0.12cm under the room temperature, place on the adhesive-bonded fabric dressing and fix according to the both sides fixed form with film-making machine;
I) at medicated layer opposite side sticking glass paper, the commodity of this Chinese medicine pad pasting pericardium pad pasting of protecting by name.
Test example 1: protect the anti-myocardial infarction test of pericardium pad pasting
Get 70 rats, 10 every group, be divided into saline unit, group of solvents, nitro-dur group at random, protect pericardium pad pasting group, be respectively 20mg/kg, l0mg/kg, three dosage groups of 5mg/kg and protect pericardium powder group 20mg/kg, totally 7 dosage groups.Each group is each rat chest back second day local medicine that pastes that lose hair or feathers before coronary artery ligation all, fixing sub-cage rearing, successive administration three days, change dressings every day once, changed dressings in the 4th day back one hour, carry out the coronary ligation art respectively, ethanol anesthesia thought-read electrograph after 24 hours, the clip heart is measured myocardial infarct size (mis) result and is shown:
Table l, protect the pericardium pad pasting to the rat coronary ligation after myocardial infarction area (mis) influence n=l0
| Sequence number | Group | Dosage g/kg | Body weight | ????％mis |
| ????1 | Saline | ????248.7±25.0 | ????34.7±3.3 | |
| ????2 | Solvent | ????256.7±32.8 | ????33.3±6.6 | |
| ????3 | Protect the pericardium pad pasting | ????5 | ????224.2±20.2 | ????35.8±4.0 |
| ????4 | ????10 | ????248.3±28.9 | ????27.40±3.7 Δ | |
| ????5 | ????20 | ????266.5±29.6 | ????24.1±5.6 **Δ?? | |
| ????6 | Protect pericardium powder | ????20 | ????24.5±24.0 | ????30.5±6.4?????? |
| ????7 | Nitroderm TTS | ????0.0125 | ????259.1±29.3 | ????27.4±3.14 Δ???? |
*With ratio of solvent P＜0.01,
*With ratio of solvent, with powder than P＜0.05, Δ and powder are than P＜0.05.
Test example 2: protect the pericardium pad pasting and resist myocardial ischemia to lactic acid dehydrogenase in the serum (LDH) effect of creatine phosphokinase (CPK) and malonaldehyde
(MDA) effect of Sheng Gaoing sees Table 2.
(after the ligation 24 hours) protect the pericardium pad pasting to rat arteria coronaria knot back to LDH, CPK, MDA content influence in the serum.
| Sequence number | Group | Dosage g/kg | The LDH normal value | The CPK normal value | The MDA normal value | After the ligation 24 hours | ||
| ??LDH a(ul -1) | ?CPK b(u/ml -1) | ???MDA a(umol/ml -1) | ||||||
| ??1 | Saline | ??4137±513.4 | ?97.97±39.31 | ???8.03±1.99 | ||||
| ??2 | Solvent | ??4165±433.4 | ?91.23±13.19 | ???8.62±0.91 | ||||
| ? ? ??3 | Protect the pericardium pad pasting | ????5 ? ????10 ? ????20 | ? ?2350± ? ?795.45 ? | ? ??21.90± ? ??6.04 ? | ? ??5.25± ? ??0.78 ? | ??2826±517.7 **? ??2498 **±574.9 ? ??2399 Δ**±471.9 | ??29.06±5.60 ΔΔ? ??24.89 ΔΔ±4.49 ? ??37.86 Δ**14.04 | ???5.97±1.98 **? ???5.62 **±0.71 ? ???5.06 Δ**±0.51 |
| ? ??4 ? | Protect pericardium powder | ? ????20 ? | ?2350± ? ?795.45 | ??21.90± ? ??6.04 | ??5.25± ? ??0.78 | ??2947±oo **514.4 ? | ? ??49.69± **9.08 ? | ? ???5.72± **0.47 ? |
| ??5 | Nitroderm TTS | ?2350± ? ?795.45 | ??21.90± ? ??6.04 | ??5.25± ? ??0.78 | ??2081± **334.0 ? | ? ??14.66± **5.76 ? | ? ???4.82± **0.77 ? | |
With ratio of solvent
*P＜0.05,
*P＜0.01,
With powder than AP＜0.05, Δ Δ P＜0.01,
The nitroderm TTS group is with guarantor's pericardium each dosage group of pad pasting and protect pericardium powder oP＜0.05, P＜0.01,
Protect each group of pericardium pad pasting and protect pericardium powder than Δ P＜0.01.
Test example 3: protect the pericardium pad pasting and improve variation of ischemic ECG ST section and anti-arrhythmia effect
See Table 3, protect the pericardium pad pasting to the rat coronary ligation after electrocardio influence n=10
| Sequence number | Group | Dosage (g/kg) | The S-T section a-10 -1mv | Arrhythmia b |
| ????1 | Saline | ????1.91±0.64 | ????7/10 | |
| ????2 | Solvent | ????2.08±0.56 | ????9/10 | |
| ????3 | Protect the pericardium pad pasting | ????5 | ????-0.4±1.0 ** | ????5/10 |
| ????4 | Protect the pericardium pad pasting | ????lO | ????1.22±1.0 * | ????2/10 |
| ????5 | Protect the pericardium pad pasting | ????20 | ????0.91±1.1 * | ????1/10 |
| ????6 | Protect pericardium powder | ????20 | ????0.23±1.49 * | ????1/10 |
| ????7 | Nitro-dur | ????0.0125 | ????0.14±1.17 ** | ????3/10 |
With the group of solvents ratio
*P＜0.05,
*P＜0.01
The ST section changes on the occasion of being liter, and negative value is for descending.
Test example 4: ligation causes the effect of myocardial ischemia after-contraction infringement to rat coronary artery to protect the pericardium pad pasting
The heart rate that records with multi-functional physiograph during myocardial ischemia behind the coronary ligation, blood pressure, it is little that left ventricular systolic pressure peak value and group of solvents are compared difference, but compare the left indoor pressure maximum rate with group of solvents, the maximal velocity of contraction of cardiac muscle fiber during zero load, the numerical value of the actual measurement maximal rate of myocardial contraction composition is big (P＜0.05 or P＜0.01), big (P＜0.05 or P＜0.01) the group of solvents left ventricular ejection time percentage rate (%) of percentage rate (%) that accounts for preceding each parameter value of operation improves nearly 2 times, protect pericardium pad pasting group left ventricular ejection time percentage rate (%) and improve, illustrate that ligation causes myocardial ischemia after-contraction infringement to a certain degree antagonism is arranged guarantor's pericardium pad pasting to rat coronary artery also than group of solvents little (P＜0.05 or P＜0.01).
Protect the pericardium pad pasting to coronary ligation after during myocardial ischemia chamber, left side diastasis pressure, left indoor pressure negative change maximum rate and group of solvents than numerical value lower (P＜0.05 or P＜0.01) left indoor pressure negative maximum rate, change percentage rate and also change percentage rate (%) that maximum rate accounts for parameter value before the operation (P＜0.05 or P＜0.01) greatly than group of solvents little (P＜0.05 or P＜0.01) left indoor pressure negative.Mean arterial pressure * heart rate * three products of left ventricular ejection time are compared its percentage rate (%) also lower (P＜0.05 or P＜0.01) as the reaction myocardial oxygen consumption with group of solvents.Illustrate that guarantor's pericardium pad pasting causes the myocardial relaxation functional lesion that takes place behind the myocardial ischemia to the rat coronary ligation certain protection effect is also arranged.
The Chinese medicine pad pasting control angina pectoris of control angina pectoris of the present invention shows that by 105 routine experimental group cases and 56 routine matched group case clinical observation on the therapeutic effect results it improves total effective rate to angina pectoris is 90.48%; It is 66.67% that the ischemic electrocardiogram is improved total effective rate; Can reduce myocardial oxygen consumption, improve the hemorheology mechanics, can obviously reduce whole blood contrast viscosity, plasma viscosity and fibronectin, the erythrocyte electrophoresis rate obviously increases; Can reduce TXB2 in the blood (thromboxane), increase 6-keto-PGE
2(expansion angiogenic substance); Can reduce traditional Chinese medical science integrated value and disease integration (observation of curative effect is as follows).
Test example 5: protect the clinical observation of pericardium pad pasting
It is 90.48% to see table 4 for details that angina pectoris is improved effective percentage.
Table 1
| Group | Case | Produce effects example number % | Effective routine number % | Invalid routine number % | Increase the weight of routine number % | Total effective rate example number % |
| Checking group matched group | ??105 ??56 | ??58(55.24) ??20(35.71) | ??37(35.24) ??25(44.01) | ??10(9.52) ??11(19.64) | ????0 ????0 | ????95(90.48) ????45(80.36) |
Two groups of Ridit analyze u=2.3237, P＞0.05, two group no significant difference
Two groups of angina pectoriss improve persistent period and attack times comparison (comparing in month before and after the treatment), see table 5 for details
Table 5
| Group | The example number | Attack times (inferior/week) | Persistent period (min) | ||||
| Before controlling | After controlling | Difference | Before controlling | After controlling | Difference | ||
| Checking group (protecting the pericardium pad pasting) | ??105 ? | ? ??13.09±13.89 ? | ? ??3.21±6.92 ? | ? ??9.88±10.93 ? | ? ??7.63±5.08 ? | ? ??2.10±2.87 ? | ? ??5.52±5.30 ? |
| Matched group (protecting pericardium powder) | ??56 ? | ? ??13.88±12.43 ? | ? ??4.11±4.44 ? | ? ??9.79±12.17 ? | ? ??9.37±8.66 ? | ? ??2.58±2.52 ? | ? ??6.79±8.98 ? |
All there are obvious minimizing (P＞0.01) angina pectoris attacks number of times and persistent period after two groups of treatments before treating, and two groups of curative effects are approximate.
Improvement has obvious curative effects to the ischemic electrocardiogram to protect pericardium pad pasting treatment back, and total effective rate is 66.67%, sees table 6 for details.
Table 6
| Group | The example number | Produce effects example number % | Effective routine number % | Invalid routine number % | Total effective rate example number % |
| Checking group (protecting the pericardium pad pasting) | ??105 | ????26(24.76％) | ????44(41.91％) | ????35(33.33％) | ??70(66.67％) |
| Matched group (protecting pericardium powder) | ??56 | ????8(14.29％) | ????23(41.07％) | ????25(44.64％) | ??31(55.36％) |
Two groups of Ridit analyze, and it is approximate that u=0.1622 P＞0.05, two a group electrocardiogram improves curative effect.
Can reduce tcm syndrome integration ratio after the treatment of guarantor's pericardium pad pasting and see table 7 for details.
Table 7
| Group | The example number | Before the treatment | After the treatment | Difference before and after the treatment |
| Checking group (protecting the pericardium pad pasting) | ??105 | ??13.26±4.34 | ???6.15±3.56 | ??7.61±5.46 |
| Matched group (protecting pericardium powder) | ??56 | ??12.00±3.52 | ???6.16±2.98 | ??6.02±4.03 |
All significantly decline (P＜0.01) of treatment back before the two group inte gration values treatments
After protecting the treatment of pericardium pad pasting, obviously reduce, see table 8 for details with the number and the consumption of Western medicine sorbitrate.
Table 8
| Group | Use sorbitrate before the treatment | Use sorbitrate after the treatment | Difference | ||
| Example number (%) | Average consumption (mg) | Example number (%) | All measure (mg) | ||
| Protect pericardium pad pasting n=105 | ??82(78.1) ? | 138.62±116.1 ? | ?43(40.95) ? | 52.72108.55 ? | ?85.88108.55 ? |
| Protect pericardium powder n=56 | ??38(67.86) ? | 87.23±91.48 ? | ?23(41.07) ? | 44.2065.43 ? | ?43.0462.82 ? |
Checking group treatment back before the treatment with the number of sorbitrate and consumption has remarkable minimizing (P＜0.01) and after the treatment of control group preceding number and the consumption of treatment with sorbitrate minimizing is also arranged, but be inferior to the checking group.
Can improve ischemia disposition cardiac function total effective rate after the treatment of guarantor's pericardium pad pasting is 66.67%, sees table 9 for details.
Table 9 pair cardiac function influence [example (%)]
| The project group | Cardiac function (pumping function+contractile function) | ||||
| Produce effects [n%] is [n%] invalid [n%] total effectively [n%] effectively | |||||
| Checking group (n=21) | Pumping function (CO.SV.CI) contractile function (PEP) cardiac function (pump+contraction) | 3(14.29) 4(19.05) 3(14.29) | 11(52.38) 10(47.62) 11(52.38) | 7(33.33) 7(33.33) 7(33.33) | 14(66.67) 14(66.67) 14(66.67) |
| Matched group (n=20) | Pumping function (CO.SV.CI) contractile function (PEP) cardiac function (pump+contraction) | 1(5.00) 1(5.00) 1(5.00) ? | 11(55.00) 7(35.00) 11(55.00) ? | 8(40.00) 12(60.00) 8(40.00) ? | 12(60.00) 8(40.00) 12(60.00) ? |
Can reduce myocardial oxygen consumption after protecting the treatment of pericardium pad pasting, see table 10 for details.
The influence of table 10 couple HR, SBP and RPP
| Group | HR (inferior/minute) (heart rate) | SBR (mmHg) systolic pressure | RPP (myocardial oxygen consumption) | |
| Checking group (n=105) | Control the back difference before controlling | ????79.36±9.67 ????76.71±6.91 *? ????3.57±6.98 | ????142.1±18.24 ????134.54±17.01 **? ????9.38±13.59 | ????11272.91±2397.14 ????1082.05±1663.33 **Δ? ????1532.99±1803.41Δ |
| Matched group (n=56) | Control the back difference before controlling | ????76.07±10.01 ????74.82±8.37 ? ????3.48±4.67 | ????140.80±13.59 ????136.45±14.01 ? ????8.04±8.66 | ????10557.84±2056.00 ????10148.89±1426.40 ? ????917.93±912.52 |
The Chinese medicine pad pasting control angina pectoris of control angina pectoris of the present invention and nitro-dur experiment contrast show that the mechanism of action of Chinese medicine pad pasting of the present invention and nitroglycerin treatment angina pectoris is proximate, all can blood vessel dilating, reduce myocardial oxygen consumption, improve myocardial ischemia-anoxemia, improve the equilibrium of supply and demand of myocardium oxygen, the platelet aggregation of reduction is arranged and adhere to, reduce thrombotic effect, the effect that improves cardiac function is arranged.Clinical in the Electrocardiographic improvement rate of ischemic, Chinese medicine pad pasting of the present invention is better than nitro-dur.Produce after the nitro-dur medication headache, dizzy, feel sick, vomiting etc. is certain pays effect, and serious drug resistance is arranged, and Chinese medicine pad pasting of the present invention does not have the effect of obviously paying, and has no drug resistance.
Attached: the clinical verification curative effect determinate standard:
Clinical efficacy criterion is carried out efficacy evaluation with reference to Ministry of Public Health bureau of drug administration " Clinical Researches of New Drugs guideline " in 1993 and " new Chinese medicine is treated the clinical research guideline of the thoracic obstruction (angina pectoris) ".
1, the angina pectoris clinical efficacy is judged
Produce effects: the equal extent fatigue does not cause that angina pectoris attacks or attack times reduce 〉=80% after the medication;
Effectively: the angina pectoris attacks number of times reduces 50% ~ 79% after the medication;
Invalid: the angina pectoris attacks number of times reduces＜50% after the medication;
Increase the weight of: angina pectoris attacks number of times, degree and persistent period increase the weight of after the medication.
2, ECG curative effect
Produce effects: resting electrocardiogram recovers normal
Effectively: the resting electrocardiogram ischemic ST descends more than the treatment back rise 0.05mV, or the T ripple that mainly leads be inverted shoal 〉=50%, or the T ripple by smooth transfer to upright;
Invalid: resting electrocardiogram is preceding basic identical with treatment;
Increase the weight of: resting electrocardiogram ST section reduces more than the 0.05mV before the treatment, and the negative T wave that mainly leads deepens 〉=50%, or upright T ripple flattens smoothly, or smooth T ripple transfers inversion to.
3, card marquis criterion of therapeutical effect
Produce effects: treatment back card marquis integrated value descends 〉=60%;
Effectively: treatment back card marquis integrated value descends 30% ~ 59%;
Invalid: treatment back card marquis integrated value descends＜30%;
Increase the weight of: treatment back card marquis integrated value rises;
4, clinical symptoms criterion of therapeutical effect
Produce effects: treatment back transference cure or alleviate two degree, i.e. severe → slight;
Effectively: once treating the back sx, i.e. severe → moderate, or moderate → slight;
Invalid: treatment back symptom does not have obvious improvement;
Increase the weight of: treatment back severity of symptoms.
5, angina pectoris attacks number of times and sorbitrate decrement comprehensive therapeutic effect standard after two groups of case medications:
Produce effects: after the medication angina pectoris do not show effect or attack times and sorbitrate consumption all reduce 〉=80%;
Effectively: angina pectoris attacks number of times and sorbitrate consumption reduce all 50% ~ 79% after (1) medication;
(2) angina pectoris does not show effect or attack times minimizing 〉=80%, and the sorbitrate consumption reduces＜50%;
Invalid: after (1) medication angina pectoris attacks number of times and sorbitrate consumption all reduce＜50%;
(2) minimizing＜50% of angina pectoris attacks number of times and the minimizing 〉=80% of sorbitrate consumption or sorbitrate consumption reduce 50% ~ 79% after the medication;
Increase the weight of: angina pectoris attacks number of times and sorbitrate consumption all increase after the medication.
Claims (17)
- One kind the prevention and the treatment angina pectoris external Chinese medicine pad pasting; form by back lining materials, medicated layer and protecting film; medicated layer wherein is made up of matrix type adjuvant 23～25%, middle pharmaceutically active ingredient 68～70% and plasticizer 7%, and middle pharmaceutically active ingredient is to select for use the prescription that contains the following traditional Chinese medicines material to make:Styrax 3-7 part, Borneolum Syntheticum 1-3 part, Benzoinum 1-3 part and Rhizoma Acori Graminei 1-3 part.
- 2. according to the Chinese medicine pad pasting of the described control angina pectoris of claim 1, wherein middle pharmaceutically active ingredient is to select for use the prescription that contains the following traditional Chinese medicines material to make:1.93 parts of 5.2 parts of Styrax, 1.93 parts of Borneolum Syntheticums, 1.93 parts of Benzoinumes and Rhizoma Acori Graminei.
- 3. according to the Chinese medicine pad pasting of the described control angina pectoris of claim 1, wherein middle pharmaceutically active ingredient is to select for use the prescription that contains the following traditional Chinese medicines material to make:Styrax 3-7 part, Borneolum Syntheticum 1-3 part, Benzoinum 1-3 part, Rhizoma Acori Graminei 1-3 part Rhizoma Cyperi 1-3 part, Radix Aucklandiae 1-3 part, Lignum Dalbergiae Odoriferae 1-3 part, Lignum Santali Albi 1-3 part, Lignum Aquilariae Resinatum 1-3 part, Radix Angelicae Dahuricae 1-3 part, Flos Caryophylli 1-3 part and Bulbus Allii Macrostemonis 1-3 part.
- 4. according to the Chinese medicine pad pasting of the described control angina pectoris of claim 3, wherein middle pharmaceutically active ingredient is to select for use the prescription that contains the following traditional Chinese medicines material to make:1.93 parts of 5.2 parts of Styrax, 1.93 parts of Borneolum Syntheticums, 1.93 parts of Benzoinumes, 1.93 parts of 1.93 portions of Rhizoma Cyperis of Rhizoma Acori Graminei, 1.93 parts of the Radix Aucklandiae, 1.93 parts of Lignum Dalbergiae Odoriferaes, 1.93 parts in Lignum Santali Albi, 1 part of Lignum Aquilariae Resinatum, 1.93 parts of the Radixs Angelicae Dahuricae, 1 part of Flos Caryophylli and Bulbus Allii Macrostemonis.
- 5. according to the Chinese medicine pad pasting of claim 1 or 3 described control angina pectoris, wherein middle pharmaceutically active ingredient is to select for use the prescription that contains the following traditional Chinese medicines material to make:Styrax 3-7 part, Borneolum Syntheticum 1-3 part, Benzoinum 1-3 part, Rhizoma Acori Graminei 1-3 part Rhizoma Cyperi 1-3 part, Radix Aucklandiae 1-3 part, Lignum Dalbergiae Odoriferae 1-3 part, Lignum Santali Albi 1-3 part, Lignum Aquilariae Resinatum 1-3 part, Radix Angelicae Dahuricae 1-3 part, Flos Caryophylli 1-3 part, Bulbus Allii Macrostemonis 1-3 part, Rhizoma Chuanxiong 3-7 part, Radix Salviae Miltiorrhizae 3-7 part, Radix Notoginseng 3-7 part, Radix Angelicae Sinensis 1-3 part, Radix Paeoniae Rubra 1-3 part, Olibanum 1-3 part, Myrrha 1-3 part, Rhizoma Corydalis 1-3 part and Radix Curcumae 1-3 part.
- 6. according to the Chinese medicine pad pasting of any one described control angina pectoris in the claim 5, wherein middle pharmaceutically active ingredient is to select for use the prescription that contains the following traditional Chinese medicines material to make:1.93 parts of 5.2 parts of Styrax, 1.93 parts of Borneolum Syntheticums, 1.93 parts of Benzoinumes, 1.93 parts of 1.93 portions of Rhizoma Cyperis of Rhizoma Acori Graminei, 1.93 parts of the Radix Aucklandiae, 1.93 parts of Lignum Dalbergiae Odoriferaes, 1.93 parts in Lignum Santali Albi, 1 part of Lignum Aquilariae Resinatum, 1.93 parts of the Radixs Angelicae Dahuricae, 1 part of Flos Caryophylli, 5.2 parts of Rhizoma Chuanxiongs, 5.2 parts of Radix Salviae Miltiorrhizaes, 5.2 parts of Radix Notoginseng, 1.93 parts of Radix Angelicae Sinensis, 1.93 parts of Radix Paeoniae Rubra, 1.93 parts of Olibanums, 1.93 parts of Myrrhas, 1.93 parts of Rhizoma Corydalis, 1.93 parts of Radix Curcumaes and Bulbus Allii Macrostemonis.
- 7. according to the Chinese medicine pad pasting of claim 1,3 or 5 described control angina pectoris, wherein middle pharmaceutically active ingredient is to select for use the prescription that contains the following traditional Chinese medicines material to make:Styrax 3-7 part, Borneolum Syntheticum 1-3 part, Benzoinum 1-3 part, Rhizoma Acori Graminei 1-3 part Rhizoma Cyperi 1-3 part, Radix Aucklandiae 1-3 part, Lignum Dalbergiae Odoriferae 1-3 part, Lignum Santali Albi 1-3 part, Lignum Aquilariae Resinatum 1-3 part, Radix Angelicae Dahuricae 1-3 part, Flos Caryophylli 1-3 part, Bulbus Allii Macrostemonis 1-3 part and Rhizoma Chuanxiong 3-7 part Flos Chrysanthemi 1-4 part and Semen Cassiae 1-4 part.
- 8. according to the Chinese medicine pad pasting of any one described control angina pectoris among the claim 1-4, wherein middle pharmaceutically active ingredient is to select for use the prescription that contains the following traditional Chinese medicines material to make:5.2 parts of Styrax, 1.93 parts of Borneolum Syntheticums, 1.93 parts of Benzoinumes, 1.93 parts of 1.93 portions of Rhizoma Cyperis of Rhizoma Acori Graminei, 1.93 parts of the Radix Aucklandiae, 1.93 parts of Lignum Dalbergiae Odoriferaes, 1.93 parts in Lignum Santali Albi, 1 part of Lignum Aquilariae Resinatum, 1.93 parts of the Radixs Angelicae Dahuricae, 1 part of Flos Caryophylli, 5.2 parts of Rhizoma Chuanxiongs, 5.2 parts of Radix Salviae Miltiorrhizaes, 5.2 parts of Radix Notoginseng, 1.93 parts of Radix Angelicae Sinensis, 1.93 parts of Radix Paeoniae Rubra, 1.93 parts of Olibanums, 1.93 parts of Myrrhas, 1.93 parts of Rhizoma Corydalis, 1.93 parts of Radix Curcumaes, 1.93 parts of Bulbus Allii Macrostemonis2.87 parts of Flos Chrysanthemis, 1.93 parts of Semen Cassiaes.
- 9. according to the Chinese medicine pad pasting of claim 1,3,5 or 7 described control angina pectoris, wherein middle pharmaceutically active ingredient is to select for use the prescription that contains the following traditional Chinese medicines material to make:Styrax 3-7 part, Borneolum Syntheticum 1-3 part, Benzoinum 1-3 part, Rhizoma Acori Graminei 1-3 part Rhizoma Cyperi 1-3 part, Radix Aucklandiae 1-3 part, Lignum Dalbergiae Odoriferae 1-3 part, Lignum Santali Albi 1-3 part, Lignum Aquilariae Resinatum 1-3 part, Radix Angelicae Dahuricae 1-3 part, Flos Caryophylli 1-3 part, Bulbus Allii Macrostemonis 1-3 part and Rhizoma Chuanxiong 3-7 part Flos Chrysanthemi 1-4 part, Semen Cassiae 1-4 part, Radix Astragali 1-3 part, Caulis Polygoni Multiflori 1-3 part and Radix Puerariae 1-4 part.
- 10. according to the Chinese medicine pad pasting of the described control angina pectoris of claim 9, wherein middle pharmaceutically active ingredient is to be made by the Chinese crude drug of following consumption:2.87 parts of 5.2 parts of Styrax, 1.93 parts of Borneolum Syntheticums, 1.93 parts of Benzoinumes, 1.93 parts of 1.93 portions of Rhizoma Cyperis of Rhizoma Acori Graminei, 1.93 parts of Lignum Dalbergiae Odoriferaes, 1.93 parts in Lignum Santali Albi, 1 part of Lignum Aquilariae Resinatum, 1.93 parts of the Radixs Angelicae Dahuricae, 1 part of Flos Caryophylli, 5.2 parts of Rhizoma Chuanxiongs, 5.2 parts of Radix Salviae Miltiorrhizaes, 5.2 parts of Radix Notoginseng, 1.93 parts of Radix Angelicae Sinensis, 1.93 parts of Radix Paeoniae Rubra, 1.93 parts of Olibanums, 1.93 parts of Myrrhas, 1.93 parts of Rhizoma Corydalis, 1.93 parts of Radix Curcumaes, 2.87 parts of 1.93 parts of Flos Chrysanthemis of Bulbus Allii Macrostemonis, 1.93 parts of the Radixs Astragali, 1.93 parts of Caulis Polygoni Multiflori, 1.93 parts of Semen Cassiaes and Radix Puerariaes.
- 11. according to the Chinese medicine pad pasting of the described control angina pectoris of claim 10, wherein middle pharmaceutically active ingredient is to be made by the Chinese crude drug of following consumption:Rhizoma Chuanxiong 234g Lignum Santali Albi 87g Radix Curcumae 87g Lignum Aquilariae Resinatum 45g Rhizoma Cyperi 87gLignum Dalbergiae Odoriferae 87g Olibanum 87g Myrrha 87g Flos Chrysanthemi 129g Flos Caryophylli 45gRadix Angelicae Sinensis 87g Radix Angelicae Dahuricae 87g Bulbus Allii Macrostemonis 87g Rhizoma Acori Graminei 87g Radix Salviae Miltiorrhizae 234gBenzoinum 87g Radix Astragali 87g Radix Paeoniae Rubra 87g Rhizoma Corydalis 87g Caulis Polygoni Multiflori 87gSemen Cassiae 87g Styrax 234g Borneolum Syntheticum 87g Radix Notoginseng 234g Radix Puerariae 129g
- 12. according to the Chinese medicine pad pasting of any one described control angina pectoris among the claim 1-11, wherein middle pharmaceutically active ingredient 68%, polyvinyl alcohol 25% and glycerol 7%.
- 13. the preparation method of any one described control angina pectoris external Chinese medicine pad pasting is characterized in that it comprises the following steps: among the claim 1-2A) Rhizoma Acori Graminei with adding decocting in water 10 ~ 12 hours, the volatile oil that extractive distillation goes out, water cooking liquid filters, filtrate is condensed into thick paste, adding amount of alcohol is 60%, is stirred well to fully evenly, leaves standstill 24 hours, draws supernatant, the precipitation part filters, and filtrate decompression reclaims ethanol, and reconcentration becomes thick paste standby;B) the ethanol of Benzoinum with 9 times of amounts, reflux, extract, 2 times, each 1 hour, filter, 2 filtrates are merged decompression, reclaim ethanol, it is standby that medicinal liquid is condensed into thick paste;C) Borneolum Syntheticum powder is broken into superfine powder and is equipped with, Styrax is standby;D) with step a), b) in the thick paste, the fine powder in the step c) that make all mix and stir, produce or the bubble complete obiteration to there being minute bubbles, left standstill 10 ~ 15 minutes;E) the mixing thick paste in the step d), matrix type adjuvant and glycerol three are fully mixed, stir, do not produce or the bubble complete obiteration, left standstill 20 ~ 30 minutes, put system film in the film-making machine medicine groove to there being minute bubbles;F) the medicine film in the step g) is dry at normal temperatures or below 40 ℃, cut into lamellar after the molding, place on the adhesive-bonded fabric dressing and fix according to the both sides fixed form;G) paste covering at pastille pad pasting layer opposite side.
- 14. the preparation method of any one described control angina pectoris external Chinese medicine pad pasting is characterized in that it comprises the following steps: among the claim 3-5A) Rhizoma Chuanxiong, Radix Curcumae, Radix Angelicae Sinensis, Rhizoma Acori Graminei, Olibanum, Myrrha 6 are distinguished the flavor of Chinese crude drugs with adding decocting in water 10 ~ 12 hours, the volatile oil that extractive distillation goes out, water cooking liquid filters, and filtrate is condensed into thick paste, adding amount of alcohol is 60%, be stirred well to fully evenly, left standstill 24 hours, draw supernatant, the precipitation part filters, filtrate decompression reclaims ethanol, and reconcentration becomes thick paste standby;B) the ethanol of Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Benzoinum, the Radix Astragali, 9 times of amounts of Rhizoma Corydalis Chinese medicine adding, reflux, extract, 2 times, each 1 hour, filter, 2 filtrates are merged decompression, reclaim ethanol, it is standby that medicinal liquid is condensed into thick paste;C) it is standby Borneolum Syntheticum, Radix Notoginseng 2 flavor medicated powder to be broken into superfine powder, and Styrax is standby;D) with step a), b) in the thick paste, the fine powder in the step c) that make all mix and stir, produce or the bubble complete obiteration to there being minute bubbles, left standstill 10 ~ 15 minutes;E) the mixing thick paste in the step d), matrix type adjuvant and glycerol three are fully mixed, stir, do not produce or the bubble complete obiteration, left standstill 20 ~ 30 minutes, put system film in the film-making machine medicine groove to there being minute bubbles;F) the medicine film in the step g) is dry at normal temperatures or below 40 ℃, cut into lamellar after the molding, place on the adhesive-bonded fabric dressing and fix according to the both sides fixed form;G) paste protecting film at pastille pad pasting layer opposite side.
- 15. the preparation method of any one described control angina pectoris external Chinese medicine pad pasting is characterized in that it comprises the following steps: among the claim 5-6A) Rhizoma Chuanxiong, Lignum Santali Albi, Radix Curcumae, the Radix Aucklandiae, Flos Caryophylli, Radix Angelicae Sinensis, Rhizoma Acori Graminei, Rhizoma Cyperi, Lignum Dalbergiae Odoriferae, Bulbus Allii Macrostemonis, Flos Chrysanthemi, Lignum Aquilariae Resinatum, the Radix Angelicae Dahuricae, Olibanum, Myrrha Chinese crude drug with adding decocting in water 10 ~ 12 hours, the volatile oil that extractive distillation goes out, water cooking liquid filters, and filtrate is condensed into thick paste, adding amount of alcohol is 60%, be stirred well to fully evenly, left standstill 24 hours, draw supernatant, the precipitation part filters, filtrate decompression reclaims ethanol, and reconcentration becomes thick paste standby;B) the ethanol of Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, the Radix Astragali, Benzoinum, 9 times of amounts of Rhizoma Corydalis Chinese medicine adding, reflux, extract, 2 times, each 1 hour, filter, 2 filtrates are merged decompression, reclaim ethanol, it is standby that medicinal liquid is condensed into thick paste;C) Semen Cassiae, Caulis Polygoni Multiflori medicated powder are broken into coarse powder,,, carry out percolation with the alcohol dipping of 12 times of amounts 24 hours according to fluid extract and extractum item percolation down, the collection percolate, recovery ethanol, it is standby to be condensed into thick paste;D) it is standby Borneolum Syntheticum, Radix Notoginseng 2 flavor medicated powder to be broken into superfine powder, and Styrax is standby;E) with step a), b), c) in the thick paste, the fine powder in the step d) and the Styrax that make all mix and stir, produce or the bubble complete obiteration to there being minute bubbles, left standstill 10 ~ 15 minutes;F) the mixing thick paste in the step e), matrix type adjuvant and glycerol three are fully mixed, stir, do not produce or the bubble complete obiteration, left standstill 20 ~ 30 minutes, put system film in the film-making machine medicine groove to there being minute bubbles;G) the medicine film in the step f) is dry at normal temperatures or below 40 ℃, cut into lamellar after the molding, place on the adhesive-bonded fabric dressing and fix according to the both sides fixed form;H) paste covering at pastille pad pasting layer opposite side.
- 16. the preparation method of any one described control angina pectoris external Chinese medicine pad pasting is characterized in that it comprises the following steps: among the claim 7-8A) Rhizoma Chuanxiong, Lignum Santali Albi, Radix Curcumae, Flos Caryophylli, Radix Angelicae Sinensis, the Radix Aucklandiae, Rhizoma Acori Graminei, Rhizoma Cyperi, Lignum Dalbergiae Odoriferae, Bulbus Allii Macrostemonis, Lignum Aquilariae Resinatum, Flos Chrysanthemi, the Radix Angelicae Dahuricae, Olibanum, Myrrha Chinese crude drug with adding decocting in water 10 ~ 12 hours, the volatile oil that extractive distillation goes out, water cooking liquid filters, and filtrate is condensed into thick paste, adding amount of alcohol is 60%, be stirred well to fully evenly, left standstill 24 hours, draw supernatant, the precipitation part filters, filtrate decompression reclaims ethanol, and reconcentration becomes thick paste standby;B) the ethanol of Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, the Radix Astragali, Benzoinum, 9 times of amounts of Rhizoma Corydalis Chinese medicine adding, reflux, extract, 2 times, each 1 hour, filter, 2 filtrates are merged decompression, reclaim ethanol, it is standby that medicinal liquid is condensed into thick paste;C) Semen Cassiae flavor medicated powder is broken into coarse powder,,, carries out percolation with the alcohol dipping of 12 times of amounts 24 hours according to fluid extract and extractum item percolation down, the collection percolate, recovery ethanol, it is standby to be condensed into thick paste;D) it is standby Borneolum Syntheticum, Radix Notoginseng 2 flavor medicated powder to be broken into superfine powder;E) with step a), b), c) in the thick paste, the fine powder in the step d) that make all mix and stir, produce or the bubble complete obiteration to there being minute bubbles, left standstill 10 ~ 15 minutes;F) the mixing thick paste in the step e), matrix type adjuvant and glycerol three are fully mixed, stir, do not produce or the bubble complete obiteration, left standstill 20 ~ 30 minutes, put system film in the film-making machine medicine groove to there being minute bubbles;G) the medicine film in the step f) is dry at normal temperatures or below 40 ℃, cut into lamellar after the molding, place on the adhesive-bonded fabric dressing and fix according to the both sides fixed form;H) paste covering at pastille pad pasting layer opposite side.
- 17. the preparation method of any one described control angina pectoris external Chinese medicine pad pasting is characterized in that it comprises the following steps: among the claim 9-11A) Rhizoma Chuanxiong, Lignum Santali Albi, Radix Curcumae, Flos Caryophylli, Radix Angelicae Sinensis, Rhizoma Acori Graminei, Rhizoma Cyperi, Lignum Dalbergiae Odoriferae, Bulbus Allii Macrostemonis, Lignum Aquilariae Resinatum, Flos Chrysanthemi, the Radix Angelicae Dahuricae, Olibanum, Myrrha Chinese crude drug with adding decocting in water 10 ~ 12 hours, the volatile oil that extractive distillation goes out, water cooking liquid filters, and filtrate is condensed into thick paste, adding amount of alcohol is 60%, be stirred well to fully evenly, left standstill 24 hours, draw supernatant, the precipitation part filters, filtrate decompression reclaims ethanol, and reconcentration becomes thick paste standby;B) the ethanol of Radix Salviae Miltiorrhizae, the Radix Astragali, Radix Paeoniae Rubra, Radix Puerariae, Benzoinum, 9 times of amounts of Rhizoma Corydalis Chinese medicine adding, reflux, extract, 2 times, each 1 hour, filter, 2 filtrates are merged decompression, reclaim ethanol, it is standby that medicinal liquid is condensed into thick paste;C) Caulis Polygoni Multiflori, Semen Cassiae 2 flavor medicated powder are broken into coarse powder,,, carry out percolation with the alcohol dipping of 12 times of amounts 24 hours according to fluid extract and extractum item percolation down, the collection percolate, recovery ethanol, it is standby to be condensed into thick paste;D) it is standby Borneolum Syntheticum, Radix Notoginseng 2 flavor medicated powder to be broken into superfine powder, and Styrax is standby;E) with step a), b), c) in the thick paste, the fine powder in the step d) and the Styrax that make all mix and stir, produce or the bubble complete obiteration to there being minute bubbles, left standstill 10 ~ 15 minutes;F) the mixing thick paste in the step e), matrix type adjuvant and glycerol three are fully mixed, stir, do not produce or the bubble complete obiteration, left standstill 20 ~ 30 minutes, put system film in the film-making machine medicine groove to there being minute bubbles;G) the medicine film in the step f) is dry at normal temperatures or below 40 ℃, cut into lamellar after the molding, place on the adhesive-bonded fabric dressing and fix according to the both sides fixed form;H) paste covering at pastille pad pasting layer opposite side.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02146524 CN1262299C (en) | 2002-10-21 | 2002-10-21 | Chinese medicine adhesive film for preventing and treating coronary heart disease and angina pectoris and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02146524 CN1262299C (en) | 2002-10-21 | 2002-10-21 | Chinese medicine adhesive film for preventing and treating coronary heart disease and angina pectoris and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1491683A true CN1491683A (en) | 2004-04-28 |
| CN1262299C CN1262299C (en) | 2006-07-05 |
Family
ID=34232772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02146524 Expired - Lifetime CN1262299C (en) | 2002-10-21 | 2002-10-21 | Chinese medicine adhesive film for preventing and treating coronary heart disease and angina pectoris and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1262299C (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102940833A (en) * | 2012-10-10 | 2013-02-27 | 肥西县中医院 | Traditional Chinese medicine composition for treating coronary heart disease and preparation method thereof |
| CN103356718A (en) * | 2012-03-26 | 2013-10-23 | 天津元化生物科技有限公司 | Slowly-released permeating cardiac paste |
| CN104688962A (en) * | 2013-12-04 | 2015-06-10 | 青岛润鑫伟业科贸有限公司 | Traditional Chinese medicinal composition for treating blockage syndrome coma |
| CN104784627A (en) * | 2015-02-06 | 2015-07-22 | 肖琼 | Traditional Chinese medicine externally used film agent used for treatment surgical open or closed injury and preparation method thereof |
| CN105148153A (en) * | 2015-09-16 | 2015-12-16 | 崔皓 | Traditional Chinese medicine for treating elderly coronary heart disease unstable angina pectoris |
| CN105435196A (en) * | 2016-01-02 | 2016-03-30 | 宋士兰 | Externally-applied traditional Chinese medicine ointment for treating qi stagnation and blood stasis coronary angina pectoris with chronic gastritis and preparation method thereof |
| CN105582280A (en) * | 2016-01-21 | 2016-05-18 | 李宪秋 | Traditional Chinese medicine preparation for treating angina pectoris of coronary heart disease |
| CN108434288A (en) * | 2018-06-18 | 2018-08-24 | 马南行 | A kind of composition for heart disease prevention and treatment |
| CN109464559A (en) * | 2018-10-26 | 2019-03-15 | 杭州仁德医药有限公司 | A kind of traditional Chinese medicine plaster of resisting cardiovascular disease |
| CN111544419A (en) * | 2020-06-11 | 2020-08-18 | 王文龙 | External plaster for coronary heart disease and its film |
| CN112263661A (en) * | 2020-10-29 | 2021-01-26 | 江西中医药大学 | Compound essential oil traditional Chinese medicine composition for improving cardiovascular problems as well as preparation method and application thereof |
| CN112546125A (en) * | 2020-12-18 | 2021-03-26 | 江西中医药大学 | Ligusticum wallichii volatile oil spray and preparation method thereof |
-
2002
- 2002-10-21 CN CN 02146524 patent/CN1262299C/en not_active Expired - Lifetime
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103356718A (en) * | 2012-03-26 | 2013-10-23 | 天津元化生物科技有限公司 | Slowly-released permeating cardiac paste |
| CN102940833A (en) * | 2012-10-10 | 2013-02-27 | 肥西县中医院 | Traditional Chinese medicine composition for treating coronary heart disease and preparation method thereof |
| CN104688962A (en) * | 2013-12-04 | 2015-06-10 | 青岛润鑫伟业科贸有限公司 | Traditional Chinese medicinal composition for treating blockage syndrome coma |
| CN104784627B (en) * | 2015-02-06 | 2018-05-22 | 肖琼 | It is a kind of to be used to treat Chinese medicine external film of surgery opening or closed injury and preparation method thereof |
| CN104784627A (en) * | 2015-02-06 | 2015-07-22 | 肖琼 | Traditional Chinese medicine externally used film agent used for treatment surgical open or closed injury and preparation method thereof |
| CN105148153A (en) * | 2015-09-16 | 2015-12-16 | 崔皓 | Traditional Chinese medicine for treating elderly coronary heart disease unstable angina pectoris |
| CN105435196A (en) * | 2016-01-02 | 2016-03-30 | 宋士兰 | Externally-applied traditional Chinese medicine ointment for treating qi stagnation and blood stasis coronary angina pectoris with chronic gastritis and preparation method thereof |
| CN105582280A (en) * | 2016-01-21 | 2016-05-18 | 李宪秋 | Traditional Chinese medicine preparation for treating angina pectoris of coronary heart disease |
| CN108434288A (en) * | 2018-06-18 | 2018-08-24 | 马南行 | A kind of composition for heart disease prevention and treatment |
| CN109464559A (en) * | 2018-10-26 | 2019-03-15 | 杭州仁德医药有限公司 | A kind of traditional Chinese medicine plaster of resisting cardiovascular disease |
| CN111544419A (en) * | 2020-06-11 | 2020-08-18 | 王文龙 | External plaster for coronary heart disease and its film |
| CN111544419B (en) * | 2020-06-11 | 2023-06-23 | 王文龙 | External plaster for coronary heart disease and plaster film thereof |
| CN112263661A (en) * | 2020-10-29 | 2021-01-26 | 江西中医药大学 | Compound essential oil traditional Chinese medicine composition for improving cardiovascular problems as well as preparation method and application thereof |
| CN112546125A (en) * | 2020-12-18 | 2021-03-26 | 江西中医药大学 | Ligusticum wallichii volatile oil spray and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1262299C (en) | 2006-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108904394B (en) | Traditional Chinese medicine composition and preparation method thereof | |
| CN1262299C (en) | Chinese medicine adhesive film for preventing and treating coronary heart disease and angina pectoris and its preparing method | |
| CN1247241C (en) | Liuwei Dihuang dripping pills and its preparation | |
| CN1965966A (en) | Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1943551A (en) | External use medicine for treating and controlling chloasma and beauty composition for removing spot and whitening | |
| CN101028325A (en) | Medicinal composition containing sailonggu, and its preparation and quality control | |
| CN108404095A (en) | A kind of Chinese medicine transdermal patch promoting blood circulation and removing obstruction in channels for curing mammary gland hyperplasia | |
| CN1067901C (en) | Drug for curing migraine and its preparing method | |
| CN1297288C (en) | Medicine for treating cardiovascular disease, and its prepn. method | |
| CN1692938A (en) | Compound traditional Chinese medicine for improving eyesight and its prepn. method | |
| CN1248698C (en) | Drug for treating coronary heart disease or coronary disease and cardiac insufficiency, and its preparation method | |
| CN1883582A (en) | Pharmaceutical composition for treating liver disease and method for preparing same | |
| CN112089830A (en) | Traditional Chinese medicine incense for relieving coronary heart disease and angina pectoris and preparation process thereof | |
| CN1227023C (en) | Drug for treating coronary heart disease, angina and preparation method | |
| CN101342346A (en) | Drop pill for treating stenocardia caused by coronary disease | |
| CN1201811C (en) | Chinese medicine composition for treating myopia and preparing method thereof | |
| CN1895367A (en) | Chinese-medicinal preparation for treating coronary heart disease and angina cordis and its preparation | |
| CN1883529A (en) | A pharmaceutical composition for treating cardiovascular and cerebrovascular disease and preparation method thereof | |
| CN1899388A (en) | Shuangdan soft capsule and its preparing method | |
| CN1269515C (en) | A pharmaceutical composition for treating hypertension, externally applied paste and preparation method thereof | |
| CN1299670C (en) | Capsules for eliminating embolism and their preparation | |
| CN108143800A (en) | A kind of Chinese medicine composition for treating hypertension heart failure | |
| CN101062093A (en) | Chinese medicine composition for treating cardiovascular disease and preparing method thereof | |
| CN207125908U (en) | For coronary disease and angina pectoris paster | |
| CN1258365C (en) | Pharmacetutical composition for treating cardiovascular and cerebrovascular disease and its preparing process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: BEIJING HUAHENGHANFANG PHARMACEUTICAL TECHNOLOGY C Free format text: FORMER OWNER: MA DELIN Effective date: 20090807 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20090807 Address after: Room 21, No. 427, torch street, Changping District science and Technology Park, Beijing Patentee after: Beijing Huaheng Hanfang Pharmaceutical Technology Co.,Ltd. Address before: The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, 117 Mei Shan Road, Anhui, Hefei, China Patentee before: Ma Delin |
|
| C56 | Change in the name or address of the patentee |
Owner name: BEIJING HUAHENG HANFANG PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: |
|
| CP03 | Change of name, title or address |
Address after: 102200, room 219, block B, No. 9, front road, Changping District science and Technology Park, Beijing Patentee after: Beijing Huaheng Hanfang Pharmaceutical Co.,Ltd. Address before: 102200, room 21, 427 torch street, Changping District science and Technology Park, Beijing Patentee before: Beijing Huaheng Hanfang Pharmaceutical Technology Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220729 Address after: 230000 Room 203, building 5, No. 70, Meishan Road, Shushan District, Hefei City, Anhui Province Patentee after: Ma Delin Address before: 102200 room 219, block B, No.9 Chaoqian Road, science and Technology Park, Changping District, Beijing Patentee before: Beijing Huaheng Hanfang Pharmaceutical Co.,Ltd. |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20060705 |